XL092-201: Zanzalintinib in Recurrent or Progressive Meningioma

In this study, adults with recurrent or progressive meningioma (a type of tumor arising from the membranes surrounding the brain and spinal cord, across WHO Grades 1, 2, or 3) that has become refractory to standard treatments will participate in a single-arm, open-label trial. Because this is an open-label, single-arm study, all participating patients will receive the same investigational study treatment, zanzalintinib (an oral capsule, also known as XL092), rather than being compared against a placebo or a different drug combination.

The primary study hypothesis is that zanzalintinib will successfully control tumor growth and delay progression by blocking multiple key proteins (including c-Met, VEGFR2, AXL, and MER) that these tumors rely on to form new blood vessels, multiply, and evade the body’s immune system.

To be eligible, patients must be 18 years or older with a confirmed diagnosis of WHO Grade 1–3 meningioma that has grown or returned after standard options like surgery and radiation (or the patient must be medically ineligible for further surgery/radiation). Participants must have received at least one prior course of radiation therapy (unless medically unsafe), possess measurable tumor disease by standard neuro-oncology imaging criteria, and maintain a Karnofsky Performance Status of 60% or higher (meaning they are well enough to care for most of their personal needs and are up and moving for at least part of the day).

Participate in a Clinical Trial

Learn More